Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report

被引：0
作者：
Hirschbuehl, Klaus [1 ]
Rank, Andreas [1 ]
Pfeiffer, Tim [1 ]
Schaller, Tina [2 ]
Haeckel, Thomas [3 ]
Roeling, Joerg [4 ]
Vlasenko, Dmytro [5 ]
Trepel, Martin [1 ]
Schmid, Christoph [1 ]
机构：
[1] Univ Klinikum Augsburg, Dept Hematol & Oncol, Stenglinstr 2, D-86156 Augsburg, Germany
[2] Univ Klinikum Augsburg, Inst Pathol, Stenglinstr 2, D-86156 Augsburg, Germany
[3] Univ Klinikum Augsburg, Dept Radiol, Stenglinstr 2, D-86156 Augsburg, Germany
[4] Internist Gemeinschaftspraxis Vincentinum, Franziskanergasse 14, D-86152 Augsburg, Germany
[5] Univ Klinikum Augsburg, Dept Visceral Surg, Stenglinstr 2, D-86156 Augsburg, Germany
来源：
JOURNAL OF HEMATOLOGY | 2019年 / 8卷 / 02期
关键词：
Ponatinib; Arterial occlusive events; Vasculitis; CML;
D O I：
10.14740/jh519
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Arterial occlusive events (AOEs) such as cerebrovascular, cardiovascular and peripheral arterial events are known side effects of ponatinib, assumed due to the rapid development and increase of arteriosclerosis, while the definitive pathomechanisms therefore are still unclear. We present a case of clinically apparent large vessel vasculitis and discuss this phenomenon as a possible mechanism of AOEs beside arteriosclerosis.
引用
收藏
页码：83 / 85
页数：3
相关论文
共 10 条
  • [1] Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Caldemeyer, Lauren
    Dugan, Michael
    Edwards, John
    Akard, Luke
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 71 - 79
  • [2] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
    Cortes, J. E.
    Kim, D. -W.
    Pinilla-Ibarz, J.
    le Coutre, P.
    Paquette, R.
    Chuah, C.
    Nicolini, F. E.
    Apperley, J. F.
    Khoury, H. J.
    Talpaz, M.
    DiPersio, J.
    DeAngelo, D. J.
    Abruzzese, E.
    Rea, D.
    Baccarani, M.
    Mueller, M. C.
    Gambacorti-Passerini, C.
    Wong, S.
    Lustgarten, S.
    Rivera, V. M.
    Clackson, T.
    Turner, C. D.
    Haluska, F. G.
    Guilhot, F.
    Deininger, M. W.
    Hochhaus, A.
    Hughes, T.
    Goldman, J. M.
    Shah, N. P.
    Kantarjian, H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) : 1783 - 1796
  • [3] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Kantarjian, Hagop M.
    [J]. BLOOD, 2018, 132 (04) : 393 - 404
  • [4] Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Mauro, Michael J.
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W. N.
    Talpaz, Moshe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) : 2075 - 2088
  • [5] Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells
    Gover-Proaktor, Ayala
    Granot, Galit
    Pasmanik-Chor, Metsada
    Pasvolsky, Oren
    Shapira, Saar
    Raz, Oshrat
    Raanani, Pia
    Leader, Avi
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 189 - 199
  • [6] Ponatinib reduces viability, migration, and functionality of human endothelial cells
    Gover-Proaktor, Ayala
    Granot, Galit
    Shapira, Saar
    Raz, Oshrat
    Pasvolsky, Oren
    Nagler, Arnon
    Lev, Dorit L.
    Inbal, Aida
    Lubin, Ido
    Raanani, Pia
    Leader, Avi
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1455 - 1467
  • [7] Circulating Angiogenic Factors in Patients with Thromboangiitis Obliterans
    Hewing, Bernd
    Stangl, Verena
    Stangl, Karl
    Enke-Melzer, Kathrin
    Baumann, Gert
    Ludwig, Antje
    [J]. PLOS ONE, 2012, 7 (04):
  • [8] Ponatinib given for advanced leukemia relapse after allo-SCT
    Hirschbuehl, K.
    Rank, A.
    Pfeiffer, T.
    Slawik, H. R.
    Schlimok, G.
    Kolb, H. J.
    Schmid, C. H.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 (04) : 599 - 600
  • [9] Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
    Mayer, K.
    Gielen, G. H.
    Willinek, W.
    Muller, M. C.
    Wolf, D.
    [J]. LEUKEMIA, 2014, 28 (04) : 976 - 977
  • [10] Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
    Valent, Peter
    Hadzijusufovic, Emir
    Schernthaner, Gerit-Holger
    Wolf, Dominik
    Rea, Delphine
    le Coutre, Philipp
    [J]. BLOOD, 2015, 125 (06) : 901 - 906
1